MIPR_APLCA
ID MIPR_APLCA Reviewed; 735 AA.
AC Q9NDE8;
DT 01-JUL-2008, integrated into UniProtKB/Swiss-Prot.
DT 01-OCT-2000, sequence version 1.
DT 25-MAY-2022, entry version 50.
DE RecName: Full=MIP-related peptides;
DE AltName: Full=AMRPs;
DE Contains:
DE RecName: Full=GAAPKFF-amide;
DE Contains:
DE RecName: Full=GQAPRFF-amide;
DE Contains:
DE RecName: Full=AMAPKFF-amide;
DE Contains:
DE RecName: Full=GSPRFF-amide;
DE Contains:
DE RecName: Full=AAPRFF-amide;
DE Contains:
DE RecName: Full=QAPRFF-amide;
DE Contains:
DE RecName: Full=GSPHFI-amide;
DE Contains:
DE RecName: Full=SDPFFM-amide;
DE Contains:
DE RecName: Full=GAPRFL-amide;
DE Contains:
DE RecName: Full=GAPRFI-amide;
DE Contains:
DE RecName: Full=GAPRFV-amide;
DE Contains:
DE RecName: Full=GPPRFI-amide;
DE Contains:
DE RecName: Full=QAPRFI-amide;
DE Contains:
DE RecName: Full=LWVPGMV-amide;
DE Flags: Precursor;
GN Name=MRP;
OS Aplysia californica (California sea hare).
OC Eukaryota; Metazoa; Spiralia; Lophotrochozoa; Mollusca; Gastropoda;
OC Heterobranchia; Euthyneura; Tectipleura; Aplysiida; Aplysioidea;
OC Aplysiidae; Aplysia.
OX NCBI_TaxID=6500;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA], PROTEOLYTIC PROCESSING, SUBCELLULAR LOCATION,
RP PYROGLUTAMATE FORMATION AT GLN-462; GLN-494 AND GLN-664, AMIDATION AT
RP PHE-142; PHE-153; PHE-164; PHE-190; PHE-209; PHE-229; PHE-255; PHE-274;
RP PHE-294; PHE-317; PHE-338; PHE-359; PHE-383; PHE-407; PHE-433; PHE-467;
RP PHE-499; ILE-515; MET-552; VAL-592; LEU-601; ILE-610; VAL-619; ILE-628;
RP ILE-669 AND VAL-714, AND MASS SPECTROMETRY.
RC TISSUE=CNS;
RX PubMed=10531464; DOI=10.1523/jneurosci.19-21-09618.1999;
RA Fujisawa Y., Furukawa Y., Ohta S., Ellis T.A., Dembrow N.C., Li L.,
RA Floyd P.D., Sweedler J.V., Minakata H., Nakamaru K., Morishita F.,
RA Matsushima O., Weiss K.R., Vilim F.S.;
RT "The Aplysia mytilus inhibitory peptide-related peptides: identification,
RT cloning, processing, distribution, and action.";
RL J. Neurosci. 19:9618-9634(1999).
CC -!- FUNCTION: Has some structural and functional features similar to
CC vertebrate opioid peptides. AMRPs are inhibitory on Aplysia esophagus,
CC penis retractor muscle, and body wall muscle.
CC -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:10531464}.
CC -!- TISSUE SPECIFICITY: Expressed in the CNS and peripheral tissues (the
CC digestive tract, vasculature, and the reproductive organs).
CC -!- MASS SPECTROMETRY: [GAAPKFF-amide]: Mass=735.38; Mass_error=0.01;
CC Method=MALDI; Evidence={ECO:0000269|PubMed:10531464};
CC -!- MASS SPECTROMETRY: [GQAPRFF-amide]: Mass=820.43; Mass_error=0.01;
CC Method=MALDI; Evidence={ECO:0000269|PubMed:10531464};
CC -!- MASS SPECTROMETRY: [AMAPKFF-amide]: Mass=809.42; Mass_error=0.01;
CC Method=MALDI; Evidence={ECO:0000269|PubMed:10531464};
CC -!- MASS SPECTROMETRY: [GSPRFF-amide]: Mass=708.37; Mass_error=0.01;
CC Method=MALDI; Evidence={ECO:0000269|PubMed:10531464};
CC -!- MASS SPECTROMETRY: [AAPRFF-amide]: Mass=706.40; Mass_error=0.02;
CC Method=MALDI; Evidence={ECO:0000269|PubMed:10531464};
CC -!- MASS SPECTROMETRY: [QAPRFF-amide]: Mass=746.37; Mass_error=0.00;
CC Method=MALDI; Evidence={ECO:0000269|PubMed:10531464};
CC -!- MASS SPECTROMETRY: [GSPHFI-amide]: Mass=655.35; Mass_error=0.01;
CC Method=MALDI; Evidence={ECO:0000269|PubMed:10531464};
CC -!- MASS SPECTROMETRY: [SDPFFM-amide]: Mass=741.33; Mass_error=0.03;
CC Method=MALDI; Evidence={ECO:0000269|PubMed:10531464};
CC -!- MASS SPECTROMETRY: [GAPRFV-amide]: Mass=644.37; Mass_error=0.01;
CC Method=MALDI; Evidence={ECO:0000269|PubMed:10531464};
CC -!- MASS SPECTROMETRY: [GAPRFL-amide]: Mass=658.37; Mass_error=0.01;
CC Method=MALDI; Evidence={ECO:0000269|PubMed:10531464};
CC -!- MASS SPECTROMETRY: [GPPRFI-amide]: Mass=684.41; Mass_error=0.02;
CC Method=MALDI; Evidence={ECO:0000269|PubMed:10531464};
CC -!- MASS SPECTROMETRY: [QAPRFI-amide]: Mass=712.40; Mass_error=0.01;
CC Method=MALDI; Evidence={ECO:0000269|PubMed:10531464};
CC -!- MASS SPECTROMETRY: [LWVPGMV-amide]: Mass=799.43; Mass_error=0.00;
CC Method=MALDI; Evidence={ECO:0000269|PubMed:10531464};
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AF160191; AAF80382.1; -; mRNA.
DR RefSeq; NP_001191614.1; NM_001204685.1.
DR AlphaFoldDB; Q9NDE8; -.
DR PRIDE; Q9NDE8; -.
DR GeneID; 100533402; -.
DR CTD; 34686; -.
DR OrthoDB; 1626986at2759; -.
DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR GO; GO:0007218; P:neuropeptide signaling pathway; IEA:UniProtKB-KW.
PE 1: Evidence at protein level;
KW Amidation; Cleavage on pair of basic residues; Neuropeptide;
KW Pyrrolidone carboxylic acid; Secreted; Signal.
FT SIGNAL 1..20
FT /evidence="ECO:0000255"
FT PROPEP 21..135
FT /evidence="ECO:0000255"
FT /id="PRO_0000343305"
FT PEPTIDE 136..142
FT /note="GAAPKFF-amide"
FT /id="PRO_0000343306"
FT PEPTIDE 147..153
FT /note="GQAPRFF-amide"
FT /id="PRO_0000343307"
FT PEPTIDE 158..164
FT /note="AMAPKFF-amide"
FT /id="PRO_0000343308"
FT PROPEP 168..184
FT /id="PRO_0000343309"
FT PEPTIDE 185..190
FT /note="GSPRFF-amide"
FT /id="PRO_0000343310"
FT PROPEP 194..203
FT /id="PRO_0000343311"
FT PEPTIDE 204..209
FT /note="GSPRFF-amide"
FT /id="PRO_0000343312"
FT PROPEP 214..229
FT /note="Linker peptide"
FT /id="PRO_0000343313"
FT PEPTIDE 224..229
FT /note="AAPRFF-amide"
FT /id="PRO_0000343314"
FT PROPEP 233..249
FT /id="PRO_0000343315"
FT PEPTIDE 250..255
FT /note="GSPRFF-amide"
FT /id="PRO_0000343316"
FT PROPEP 259..267
FT /note="Linker peptide"
FT /id="PRO_0000343317"
FT PEPTIDE 269..274
FT /note="GSPRFF-amide"
FT /id="PRO_0000343318"
FT PROPEP 279..287
FT /note="Linker peptide"
FT /id="PRO_0000343319"
FT PEPTIDE 289..294
FT /note="GSPRFF-amide"
FT /id="PRO_0000343320"
FT PROPEP 298..311
FT /id="PRO_0000343321"
FT PEPTIDE 312..317
FT /note="GSPRFF-amide"
FT /id="PRO_0000343322"
FT PROPEP 321..332
FT /id="PRO_0000343323"
FT PEPTIDE 333..338
FT /note="GSPRFF-amide"
FT /id="PRO_0000343324"
FT PROPEP 342..353
FT /id="PRO_0000343325"
FT PEPTIDE 354..359
FT /note="GSPRFF-amide"
FT /id="PRO_0000343326"
FT PROPEP 363..377
FT /id="PRO_0000343327"
FT PEPTIDE 378..383
FT /note="GSPRFF-amide"
FT /id="PRO_0000343328"
FT PROPEP 387..401
FT /id="PRO_0000343329"
FT PEPTIDE 402..407
FT /note="GSPRFF-amide"
FT /id="PRO_0000343330"
FT PROPEP 412..426
FT /note="Linker peptide"
FT /id="PRO_0000343331"
FT PEPTIDE 428..433
FT /note="GSPRFF-amide"
FT /id="PRO_0000343332"
FT PROPEP 437..461
FT /id="PRO_0000343333"
FT PEPTIDE 462..467
FT /note="QAPRFF-amide"
FT /id="PRO_0000343334"
FT PROPEP 471..493
FT /id="PRO_0000343335"
FT PEPTIDE 494..499
FT /note="QAPRFF-amide"
FT /id="PRO_0000343336"
FT PROPEP 503..509
FT /id="PRO_0000343337"
FT PEPTIDE 510..515
FT /note="GSPHFI-amide"
FT /id="PRO_0000343338"
FT PROPEP 519..546
FT /id="PRO_0000343339"
FT PEPTIDE 547..552
FT /note="SDPFFM-amide"
FT /id="PRO_0000343340"
FT PROPEP 556..585
FT /id="PRO_0000343341"
FT PEPTIDE 587..592
FT /note="GAPRFV-amide"
FT /id="PRO_0000343342"
FT PEPTIDE 596..601
FT /note="GAPRFL-amide"
FT /id="PRO_0000343343"
FT PEPTIDE 605..610
FT /note="GAPRFI-amide"
FT /id="PRO_0000343344"
FT PEPTIDE 614..619
FT /note="GAPRFV-amide"
FT /id="PRO_0000343345"
FT PEPTIDE 623..628
FT /note="GPPRFI-amide"
FT /id="PRO_0000343346"
FT PROPEP 632..661
FT /note="Linker peptide"
FT /id="PRO_0000343347"
FT PEPTIDE 664..669
FT /note="QAPRFI-amide"
FT /id="PRO_0000343348"
FT PROPEP 674..705
FT /note="Linker peptide"
FT /id="PRO_0000343349"
FT PEPTIDE 708..714
FT /note="LWVPGMV-amide"
FT /id="PRO_0000343350"
FT PROPEP 715..735
FT /id="PRO_0000343351"
FT REGION 33..212
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 229..251
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 352..373
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 381..400
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 430..464
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 33..76
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 105..127
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 168..182
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 194..212
FT /note="Basic and acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 358..372
FT /note="Basic and acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 382..396
FT /note="Basic and acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 444..461
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT MOD_RES 142
FT /note="Phenylalanine amide"
FT /evidence="ECO:0000269|PubMed:10531464"
FT MOD_RES 153
FT /note="Phenylalanine amide"
FT /evidence="ECO:0000269|PubMed:10531464"
FT MOD_RES 164
FT /note="Phenylalanine amide"
FT /evidence="ECO:0000269|PubMed:10531464"
FT MOD_RES 190
FT /note="Phenylalanine amide"
FT /evidence="ECO:0000269|PubMed:10531464"
FT MOD_RES 209
FT /note="Phenylalanine amide"
FT /evidence="ECO:0000269|PubMed:10531464"
FT MOD_RES 229
FT /note="Phenylalanine amide"
FT /evidence="ECO:0000269|PubMed:10531464"
FT MOD_RES 255
FT /note="Phenylalanine amide"
FT /evidence="ECO:0000269|PubMed:10531464"
FT MOD_RES 274
FT /note="Phenylalanine amide"
FT /evidence="ECO:0000269|PubMed:10531464"
FT MOD_RES 294
FT /note="Phenylalanine amide"
FT /evidence="ECO:0000269|PubMed:10531464"
FT MOD_RES 317
FT /note="Phenylalanine amide"
FT /evidence="ECO:0000269|PubMed:10531464"
FT MOD_RES 338
FT /note="Phenylalanine amide"
FT /evidence="ECO:0000269|PubMed:10531464"
FT MOD_RES 359
FT /note="Phenylalanine amide"
FT /evidence="ECO:0000269|PubMed:10531464"
FT MOD_RES 383
FT /note="Phenylalanine amide"
FT /evidence="ECO:0000269|PubMed:10531464"
FT MOD_RES 407
FT /note="Phenylalanine amide"
FT /evidence="ECO:0000269|PubMed:10531464"
FT MOD_RES 433
FT /note="Phenylalanine amide"
FT /evidence="ECO:0000269|PubMed:10531464"
FT MOD_RES 462
FT /note="Pyrrolidone carboxylic acid"
FT /evidence="ECO:0000269|PubMed:10531464"
FT MOD_RES 467
FT /note="Phenylalanine amide"
FT /evidence="ECO:0000269|PubMed:10531464"
FT MOD_RES 494
FT /note="Pyrrolidone carboxylic acid"
FT /evidence="ECO:0000269|PubMed:10531464"
FT MOD_RES 499
FT /note="Phenylalanine amide"
FT /evidence="ECO:0000269|PubMed:10531464"
FT MOD_RES 515
FT /note="Isoleucine amide"
FT /evidence="ECO:0000269|PubMed:10531464"
FT MOD_RES 552
FT /note="Methionine amide"
FT /evidence="ECO:0000269|PubMed:10531464"
FT MOD_RES 592
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:10531464"
FT MOD_RES 601
FT /note="Leucine amide"
FT /evidence="ECO:0000269|PubMed:10531464"
FT MOD_RES 610
FT /note="Isoleucine amide"
FT /evidence="ECO:0000269|PubMed:10531464"
FT MOD_RES 619
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:10531464"
FT MOD_RES 628
FT /note="Isoleucine amide"
FT /evidence="ECO:0000269|PubMed:10531464"
FT MOD_RES 664
FT /note="Pyrrolidone carboxylic acid"
FT /evidence="ECO:0000269|PubMed:10531464"
FT MOD_RES 669
FT /note="Isoleucine amide"
FT /evidence="ECO:0000269|PubMed:10531464"
FT MOD_RES 714
FT /note="Valine amide"
FT /evidence="ECO:0000269|PubMed:10531464"
SQ SEQUENCE 735 AA; 82380 MW; F8BF80F88BB2CD14 CRC64;
MCTRPGLAAL LVLMTSCASS FSRADTQSAS AAALSAASAD AQAARQQQEQ HLVAQQQQQQ
QQQQQHSNNN EPQQRAPSLD PYYRSLLDGS QGGQLFAPAQ PVSQPDLSPD FSNPMGSSLS
QSGTPEDSDT KVDTRGAAPK FFGKKRGQAP RFFGKKRAMA PKFFGKKSSE FPTSNSEQLA
LDTRGSPRFF GKKSFPESNR EQRGSPRFFG KKRFDENVDI DERAAPRFFG KKSSGESAGD
SGYISVASRG SPRFFGKKQD DDIMIAARGS PRFFGKKRSD DNVALDLRGS PRFFGKRQSS
DLDDEISVAL RGSPRFFGKK RADDEDILLG ERGSPRFFGK KRANDENISF SLRGSPRFFG
KKRSDESDDD NIGLVARGSP RFFGKKRSDE TDDENIGLMA RGSPRFFGRK RSDGLDDGGN
IIDVATRGSP RFFGKKRSNS DSSDKSSDSA LSSSESGRQT RQAPRFFGKR YVDEHHVSKR
AAATAFPLII EARQAPRFFG KREYRYPPRG SPHFIGKRFS LYRSPGKYSL SSPYMSAKEF
KETFRRSDPF FMGKRTAELN EEGSDDFTND DTDDENEYDE TVLFKRGAPR FVGKRGAPRF
LGRRGAPRFI GRRGAPRFVG KRGPPRFIGK RDLDWYQKAL CAEADILELD DCADFLGNDD
VKRQAPRFIG RKRGEDVSER DYAQLLEALS RLQAIKQIKA RIQNEKRLWV PGMVGRRSEY
NLGPFDEFVD ESMER
